| 查看: 361 | 回复: 1 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
abcd888898银虫 (正式写手)
|
[交流]
Bydureon™ Receives Marketing Authorization in Europe 已有1人参与
|
||
|
INDIANAPOLIS, SAN DIEGO and WALTHAM, Mass., June 21, 2011 /PRNewswire via COMTEX/ -- Eli Lilly and Company (NYSE: LLY), together with Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes, Inc. (Nasdaq: ALKS), announced today that the European Commission has granted marketing authorization to BYDUREON(TM) (exenatide 2 mg powder and solvent for prolonged release suspension for injection). BYDUREON, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the first once-weekly treatment for type 2 diabetes. It delivers glycemic control in a single weekly dose and is indicated for the treatment of type 2 diabetes in adult patients in combination with metformin, a sulfonylurea, a thiazolidinedione, metformin plus a sulfonylurea or metformin plus a thiazolidinedione. |
回复此楼» 猜你喜欢
求26届aidd博导推荐
已经有4人回复
-
关于SCI杂志发表挂名
已经有32人回复
-
药物学论文润色/翻译怎么收费?
已经有103人回复
-
2026申博推荐
已经有1人回复
-
一篇扩散模型的Nature Machine Intelligence论文和Elsevier上的深度学习药物书籍
已经有1人回复
-
中国药科大学2026入学博士，药物合成和设计经验，放射化学及放射医学研究
已经有25人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- Funny English quiz in everyday（NO.7）
已经有28人回复
- Austerity vs. Europe
已经有3人回复
- 最经典的固体物理著作：CONCEPTS IN SOLIDS by P.W.Anderson
已经有776人回复
- 【求助】JPCM的状态in progress什么意思？
已经有5人回复
2楼2011-06-24 20:30:33